Clinical trial
Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic…
NCT00003612 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00003612 |
|---|---|
| Title | Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer |
| Official title | Randomized Phase II Trial of Paclitaxel, Carboplatin and rhuMAb Her-2 (Herceptin) as First-Line Chemotherapy in Patients With Metastatic Breast Cancer Who Overexpress Her-2 |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, carboplatin, paclitaxel |
| Enrollment | 92 |
| Start date | Apr 1, 1999 |
| Primary completion | Dec 1, 2005 |
| Completion | Mar 15, 2019 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 8, 2019 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: